Variable | A+ T– (N)– | A+ T+ (N)– | A+ T– (N)+ | A+ T+ (N)+ | p value |
---|---|---|---|---|---|
Response to ChEIs | |||||
MMSE score, improved/unchanged patients after 6 months (%) | 62 | 91 | 53 | 54 | 0.141 |
ADAS-cog score (0–70), improved/ unchanged patients after 6 months (%) | 62 | 18 | 56 | 55 | 0.077 |
IADL score, improved/unchanged patients after 6 months (%) | 53 | 36 | 25 | 41 | 0.218 |
PSMS score, improved/unchanged patients after 6 months (%) | 55 | 91 | 63 | 68 | 0.141 |
Rates of progression | Mean (95% confidence interval) | p value | |||
MMSE score, decline/year | −1.7 (−3.1, −0.2) | −1.4 (−3.0, 0.3) | −1.1 (−2.0, −0.1) | −2.9 (−4.1, − 1.8) | 0.361 |
ADAS-cog score (0–70), decline/year | −1.7 (−3.3, −0.2) | −2.7 (−4.5, −1.0) | −2.8 (−5.1, −0.4) | −3.9 (−5.6, −2.1) | 0.286 |
IADL score, decline/year | −2.6 (−3.3, −1.9) | −3.1 (−4.8, − 1.5) | −2.8 (− 3.9, − 1.8) | −4.2 (− 5.7, − 2.7) | 0.148 |
PSMS score, decline/year | −1.7 (−2.4, −0.9) | −1.4 (−2.6, − 0.1) | − 1.2 (− 1.9, − 0.5) | −1.4 (− 2.2, − 0.7) | 0.891 |
Length in the SATS, months | 22.9 (19.6, 26.3) | 27.5 (20.3, 34.7) | 31.1 (27.1, 35.0) | 23.8 (19.9, 27.7) | 0.081 |